曲妥珠单抗联合雷莫芦单抗方案在实体瘤患者中无需 H1 抗组胺药预处理的安全性。
Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.
机构信息
Department of Pharmacy, Osaka Medical College Hospital, Takatsuki, Japan.
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
出版信息
In Vivo. 2020 Nov-Dec;34(6):3489-3493. doi: 10.21873/invivo.12189.
Abstract
BACKGROUND/AIM: To prevent infusion-related reactions (IRRs), H1-antihistamines (HAT) are recommended as a premedication for monoclonal antibodies, such as Ramucirumab (RAM), even though there are HAT-related side effects, such as drowsiness and dizziness. Here, we investigated the safety of HAT-free RAM regimens in patients with solid cancer.
PATIENTS AND METHODS
We retrospectively reviewed the patients with solid cancer receiving RAM without HAT at Osaka Medical College Hospital between 2015 and 2019.
RESULTS
Among the 123 registered patients, 58 were identified as eligible. The total number of RAM infusions was 291, and the median number of RAM administration was 4 cycles (range=1-23 cycles). IRRs were not observed in any patient.
CONCLUSION
Although our data are preliminary and limited, HAT-free RAM regimens may be a treatment option for cancer patients having a significant risk of developing HAT-related side effects. Further studies are needed to confirm the safety of HAT-free RAM regimens.
摘要
背景/目的：为了预防输注相关反应（IRR），推荐使用 H1 抗组胺药（HAT）作为单克隆抗体（如 Ramucirumab，RAM）的预处理药物，尽管 HAT 会引起一些副作用，如嗜睡和头晕。在此，我们研究了 HAT 免费 RAM 方案在实体瘤患者中的安全性。
患者和方法
我们回顾性分析了 2015 年至 2019 年在大阪医科大学医院接受 RAM 治疗且未使用 HAT 的实体瘤患者。
结果
在 123 名登记患者中，有 58 名符合条件。共进行了 291 次 RAM 输注，中位数 RAM 给药次数为 4 个周期（范围=1-23 个周期）。未观察到任何患者出现 IRR。
结论
尽管我们的数据初步且有限，但 HAT 免费 RAM 方案可能是具有 HAT 相关副作用高风险的癌症患者的一种治疗选择。需要进一步的研究来确认 HAT 免费 RAM 方案的安全性。
相似文献
1
Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.曲妥珠单抗联合雷莫芦单抗方案在实体瘤患者中无需 H1 抗组胺药预处理的安全性。
In Vivo. 2020 Nov-Dec;34(6):3489-3493. doi: 10.21873/invivo.12189.
2
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.地塞米松与抗组胺药联合地塞米松预处理预防胃癌中 ramucirumab 联合 nab-紫杉醇输注相关反应的非劣效性：一项多中心回顾性研究。
Support Care Cancer. 2024 Oct 7;32(10):704. doi: 10.1007/s00520-024-08910-8.
3
Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.晚期结直肠癌患者使用雷莫芦单抗联合 FOLFIRI 治疗的输注相关反应。
Int J Clin Oncol. 2021 Nov;26(11):2025-2028. doi: 10.1007/s10147-021-02004-9. Epub 2021 Sep 2.
4
5
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.奥瑞珠单抗输注在复发型和原发进展型多发性硬化症患者中的应用经验：来自 III 期随机 OPERA I、OPERA II 和 ORATORIO 研究的结果。
Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.
6
Retrospective analysis of premedication, glucocorticosteroids, and H-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer.对头颈部癌患者使用西妥昔单抗治疗时，预防输液反应的预处理、糖皮质激素和H-抗组胺药的回顾性分析。
J Int Med Res. 2017 Aug;45(4):1378-1385. doi: 10.1177/0300060517713531. Epub 2017 Jun 12.
7
Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions.静脉注射西替利嗪进行预处理以减轻输液相关反应。
J Adv Pract Oncol. 2024 Mar;15(2):125-135. doi: 10.6004/jadpro.2024.15.2.5. Epub 2024 Mar 1.
8
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.一项评估胃肠癌患者雷莫芦单抗短时间输注安全性的前瞻性试验。
Oncologist. 2019 Feb;24(2):159-e66. doi: 10.1634/theoncologist.2018-0580. Epub 2018 Oct 10.
9
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.一项在一线伊立替康为基础的治疗后疾病进展的转移性结直肠癌患者中，联合雷莫芦单抗或伊曲珠单抗作为二线治疗的改良 FOLFOX-6 方案的随机 II 期研究。
Ann Oncol. 2016 Dec;27(12):2216-2224. doi: 10.1093/annonc/mdw412. Epub 2016 Oct 11.
10
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.回顾性比较 nab-紫杉醇联合雷莫芦单抗与紫杉醇联合雷莫芦单抗作为晚期胃癌二线治疗（重点关注腹膜转移）。
Invest New Drugs. 2020 Apr;38(2):533-540. doi: 10.1007/s10637-019-00822-3. Epub 2019 Jul 2.
引用本文的文献
1
Impact of Pre-treatment Proteinuria Progression on the Risk of Increased Proteinuria During Ramucirumab Therapy.治疗前蛋白尿进展对雷莫西尤单抗治疗期间蛋白尿增加风险的影响。
Cancer Diagn Progn. 2025 Jun 30;5(4):437-452. doi: 10.21873/cdp.10457. eCollection 2025 Jul-Aug.
2
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study.地塞米松与抗组胺药联合地塞米松预处理预防胃癌中 ramucirumab 联合 nab-紫杉醇输注相关反应的非劣效性：一项多中心回顾性研究。
Support Care Cancer. 2024 Oct 7;32(10):704. doi: 10.1007/s00520-024-08910-8.
本文引用的文献
1
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment.癌症治疗中单克隆抗体输注反应和输注率的系统评价。
Anticancer Res. 2020 Mar;40(3):1201-1218. doi: 10.21873/anticanres.14062.
2
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
3
Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.全身抗癌治疗输注反应的管理：ESMO临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216.
4
Retrospective analysis of premedication, glucocorticosteroids, and H-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer.对头颈部癌患者使用西妥昔单抗治疗时，预防输液反应的预处理、糖皮质激素和H-抗组胺药的回顾性分析。
J Int Med Res. 2017 Aug;45(4):1378-1385. doi: 10.1177/0300060517713531. Epub 2017 Jun 12.
5
6
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.雷莫芦单抗二线治疗索拉非尼一线治疗后晚期肝细胞癌患者（REACH）：一项随机、双盲、多中心、III 期临床试验。
Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.
7
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.雷莫芦单抗联合 FOLFIRI 二线治疗用于贝伐珠单抗、奥沙利铂和氟嘧啶一线治疗后进展的转移性结直肠癌患者：一项随机、双盲、多中心、III 期研究（RAISE）。
Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
8
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
9
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.雷莫芦单抗联合多西他赛对比安慰剂联合多西他赛二线治疗铂类化疗后进展的 IV 期非小细胞肺癌（REVEL）：一项多中心、双盲、随机 III 期临床试验。
Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.
10
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.帕尼单抗对比西妥昔单抗治疗化疗耐药野生型 KRAS 外显子 2 转移性结直肠癌患者（ASPECCT）：一项随机、多中心、开放标签、非劣效性的 3 期研究。
Lancet Oncol. 2014 May;15(6):569-79. doi: 10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14.
Zotero 插件